Overview

• A retrospective study of over 800 patients with relapsed/refractory T- and NK-cell lymphomas demonstrates improved survival using a sequential treatment strategy.
• The optimal sequence involves second-line small molecule inhibitors, such as duvelisib, followed by third-line epigenetic modifiers.
• Survival benefits were particularly significant in high-risk patients and those with angioimmunoblastic T-cell lymphoma, a challenging subgroup.
• The study leveraged global PETAL Consortium data and machine learning to compare 12 treatment paths, providing robust evidence for this approach.
• Researchers advocate for prospective clinical trials to validate findings and explore applications of this framework in other cancers.